BioHarvest Sciences Inc. Announces Live Quarterly Shareholder Update Event January 19, 2023, at 2:00 PM E.T.

January 11, 2023 8:00 AM EST | Source: BioHarvest Sciences Inc.

Vancouver, British Columbia, and Rehovot, Israel--(Newsfile Corp. - January 11, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB:CNVCF) ("BioHarvest" or "the Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, January 19, 2023, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

BioHarvest Sciences CEO Ilan Sobel will host this first shareholder event of 2023, and will present the Q4 2022 VINIA®  sales results, provide an update on Cannabis commercialization, and will also "unpack" the 2023 Growth Priorities which will deliver the 2023 company revenue guidance of $17M - $20M USD.

"We are entering our second full year of VINIA® commercialization, and it is remarkable how our organization has so quickly transformed into this commercial machine. I look forward to sharing new details on our 2023 Priorities, and to reiterate my confidence in this being a historical pivot year for BioHarvest Sciences", states CEO Ilan Sobel, adding "We are targeting a second consecutive year of 3x revenue growth, and to become overall cash flow positive in Q4. These are aggressive goals, but our team is mobilized to execute on a 2023 plan designed to capitalize on current market opportunities across both our polyphenol and cannabis verticals."

The presentation will be approximately 45 minutes, followed by a live question and answer session. All shareholders, media, and interested investors are welcome to join. All registrants will be emailed a recording of the session. Any questions regarding the event can be sent to

Register for free at:

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit:

BioHarvest Sciences Inc.

Ilan Sobel, Chief Executive Officer

For further information, please contact:

Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186

Facebook Twitter Linkedin Youtube

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance that we will achieve our objective of making our products available in multiple markets. There is no assurance that the Company will be successful in expanding its technology to broader medical applications or conduct clinical trials to validate the efficacy of the Company's products for new forms of medical treatments. There is no assurance that we will achieve our objective of being a leading supplier of Cannabis, whether in North America or other global markets. Delays and cost overruns may result in delays achieving our objectives obtaining market acceptance and regulatory approvals for geographic expansion are subject to risk and cannot be guaranteed. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit